I graduated from Shanghai Medical University and later came to the U.S. and obtained a PhD in molecular biology at the Medical College of Ohio. I did research in cancer biology at UPENN and then Yale as a postdoctoral associate. I completed an internal medicine residency at the Yale-affiliated Hospital of Saint Raphael program and trained in Einstein/Montefiore Medical Center during hematology and oncology fellowship. After that, I joined Cornell University Medical College and New York Presbyterian Hospital as Assistant Professor specializing in GI cancers, and clinical investigator involved in both clinical and translational research. I was the Cornell site PI for several early and late phase clinical trials including the phase 1 CXCR4 inhibitor AMD3100/Plerixafor immunotherapy trial, and wrote the protocol for an investigator-initiated trial (IIT) of high-dose IV vitamin C in solid tumors, which subsequently won a SU2C award for Cornell. In 2017, I left Cornell and joined Merck as a Director of oncology research and led several global Phase I-III immuno-oncology trials including Keynote 177 and 164 in MSI-H colorectal cancer, and Keynote 651 in non-MSI-H CRC. Most recently, I led the designing and protocol writing of a Phase III study of combinational immunotherapy vs standard of care chemotherapy in third line non-MSI-H CRC.
Although developing novel immunotherapy at Merck for cancer patients with high unmet need is very gratifying, I missed direct patient care. Thus, I returned to academic and joined Roswell Park on 8/1/2019 to focus on head and neck cancer patient care and clinical/translational research. I will also provide care for patients with lung cancer, as well as, participating in the running of phase I program to investigate safety and early efficacy of new drugs and combinations.